Biotech co Aposense signs multimillion dollar deal

Aposense Ltd. has signed a cooperation agreement with Belgium's Ion Beam Applications SA (IBA) (Euronext: IBAB), a global provider of PET radiopharmaceuticals, which will commercialize Aposense's novel apoptosis (programmed cell death) agent for molecular imaging and therapy, [18F]-ML-10. [...]

If the product is approved for marketing, IBA and Aposense will set up a joint marketing network for it. IBA will primarily focus on marketing of the molecule to radiologists in its core PET imaging and nuclear medicine market, and Aposense will market it to the referring clinical specialist market, including neurologists, oncologists, and cardiologists.
Lire l'intégralité de l'article » (Source: article de Gali Weinreb @ Globes)
Anti Boycott Israel Blog : imagerie médicale